Clinical Trials Using Pevonedistat

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pevonedistat. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-18 of 18
  • Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    This screening and multi-sub-study Phase 1b / 2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
    Location: 17 locations

  • Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated with Immunotherapy

    This phase II trial studies how well MLN4924 (pevonedistat), carboplatin, and paclitaxel work in treating patients with stage IIIB or IV non-small cell lung cancer. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat together with carboplatin and paclitaxel may work better in treating patients with non-small cell lung cancer when compared with other standard chemotherapy drugs.
    Location: 10 locations

  • Ixazomib and Pevonedistat in Treating Patients with Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

    This IB trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 8 locations

  • Pevonedistat with or without Pemetrexed Disodium and Cisplatin in Treating Patients with Malignant Mesothelioma

    This phase I / II trial studies the side effects and best dose of pevonedistat with or without pemetrexed disodium and cisplatin, and to see how well they work in treating patients with malignant mesothelioma. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat, pemetrexed disodium, and cisplatin may work better in treating patients with malignant mesothelioma.
    Location: 7 locations

  • Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

    The purpose of this study is to determine whether the combination of pevonedistat + venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax + azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.
    Location: 6 locations

  • Pevonedistat and Azacitidine in Treating Patients with Refractory or Relapsed Myelodysplastic Syndrome or Myelodysplastic Syndrome / Myeloproliferative Neoplasm Who Fail Primary Therapy

    This phase II trial studies how well pevonedistat and azacitidine work in treating patients with myelodysplastic syndrome or myelodysplastic syndrome / myeloproliferative neoplasm that has failed primary therapy, that does not respond to treatment (refractory), or has come back (recurrent). Pevonedistat and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 5 locations

  • Pevonedistat, Cytarabine, and Idarubicin in Treating Patients with Acute Myeloid Leukemia

    This phase Ib / II trial studies the side effects and best dose of pevonedistat and to see how well it works in combination with cytarabine and idarubicin in treating patients with acute myeloid leukemia. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Given pevonedistat, cytarabine, and idarubicin may work better in treating patients with acute myeloid leukemia.
    Location: 4 locations

  • Pevonedistat and Belinostat in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    This phase I trial studies side effects and best dose of pevonedistat and belinostat in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as pevonedistat and belinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 2 locations

  • Pevonedistat and Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back (relapsed) or has stopped responding to other treatments (refractory). Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Pevonedistat with Combination Chemotherapy for the Treatment of Recurrent or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of pevonedistat and how well it works with combination chemotherapy in treating adolescents and young adults with acute lymphoblastic leukemia or lymphoblastic non-Hodgkin lymphoma that has come back (recurrent) or has not responded to treatment (refractory). Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vincristine sulfate, dexamethasone, pegaspargase, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat with chemotherapy may work better in treating acute lymphoblastic leukemia or lymphoblastic non-Hodgkin lymphoma compared to chemotherapy alone.
    Location: 3 locations

  • Azacitidine, Venetoclax, and Pevonedistat in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia

    This phase I / II trial studies the best dose of venetoclax when given together with azacitidine and pevonedistat and to see how well it works in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine, venetoclax, and pevonedistat may work better in treating patients with acute myeloid leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pevonedistat and Low Dose Cytarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    This phase I trial studies the side effects and best dose of pevonedistat when given together with low dose cytarabine for the treatment of acute myeloid leukemia or myelodysplastic syndrome that has come back (relapsed) or does not respond the treatment (refractory). Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cytarabine is an anticancer drug and may disrupt the creation of deoxyribonucleic acid (DNA) which stops cancer cells from dividing and increasing in number. Giving pevonedistat together with low dose cytarabine may work better in slowing down the growth or destroying cancer cells compared to low dose cytarabine alone.
    Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

  • Pevonedistat and Ruxolitinib in Treating Participants with Myelofibrosis

    This phase I trial studies the side effects and best dose of pevonedistat when given together with ruxolitinib phosphate in treating participants with myelofibrosis. Pevonedistat and ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pevonedistat in combination with ruxolitinib may help researchers learn more about treatments for myelofibrosis.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Pevonedistat and Docetaxel in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well pevonedistat and docetaxel work in treating patients with stage IV non-small cell lung cancer or non-small cell lung cancer that has come back. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Testing the Combination of Pevonedistat with Chemotherapy for Bile Duct Cancer of the Liver

    This phase II trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study may help the study doctors find out how well pevonedistat shrinks bile duct cancer of the liver when given alone and when in combination with paclitaxel and carboplatin.
    Location: 426 locations

  • Pevonedistat with Azacitidine versus Azacitidine Alone in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

    This phase II trial studies how well pevonedistat works with azacitidine compared to azacitidine alone in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if pevonedistat with azacitidine or azacitidine alone may work better in treating patients with acute myeloid leukemia.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Pevonedistat and Decitabine in Treating Patients with High Risk Acute Myeloid Leukemia

    This phase I trial studies the side effects and best dose of pevonedistat when given together with decitabine in treating patients with high risk acute myeloid leukemia. Pevonedistat and decitabine may stop the growth of cancer cells by blocking some of the enzymes need for cell growth.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

    Pevonedistat is a medicine to treat people with blood cancers or solid tumors. The main aim of the study is to learn about the levels of pevonedistat in the blood of participants with blood cancers or solid tumors, who also have severe kidney problems or mild to moderate liver problems. The information from this study will be used to work out the best dose of pevonedistat to give people with these conditions in future studies. At the first visit, the study doctor will check who can take part in the study. This study is in 2 parts: A and B. Part A Participants will be placed into 1 of 4 treatment groups depending on how severe their kidney and liver problems are. All participants will receive 1 dose of pevonedistat as a slow injection in their vein (infusion). Then, the study doctors will check the levels of pevonedistat in the blood of the participants for 3 days after the infusion. They will also check if the participants have any side effects from pevonedistat. Participants will be asked to continue to Part B. Those who don't want to continue will visit the clinic 30 days later for a final check-up. Part B Participants who agree to participate into Part B will receive an infusion of pevonedistat on specific days during a 21-day or 28-day cycle. The cycle time will depend on what type of cancer the participants have. Participants will also be treated with standard of care medicines for their kidney and liver problems during this time. In the first cycle, the study doctors will also check the levels of pevonedistat in the blood and urine of participants for 3 days after the infusion. Participants will continue with cycles of treatment together with standard of care medicines until their condition gets worse or they have too many side effects from the treatment. When treatment has finished, participants will visit the clinic 10 days later for a final check-up.
    Location: 2 locations